Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2024 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

CHARLESTOWN, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
September 04, 2024 16:05 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
September 04, 2024 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for...
August 13, 2024 16:08 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

– Patients dosed in Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne); Dosing was well tolerated in all patients with initial data expected Q4...
August 05, 2024 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
July 01, 2024 16:19 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
July 01, 2024 08:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Joins the Russell 3000® Index

CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases,...
June 04, 2024 16:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and...
May 15, 2024 07:52 ET | Source: Solid Biosciences Inc.

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing in Phase 1/2 trialexpected Q2 2024 — —...
May 07, 2024 07:00 ET | Source: Solid Biosciences Inc.

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

— Presentations to highlight AAV manufacturing and purification improvements, vector biology updates,and a comprehensive non-clinical data overview of the company’s lead SGT-003 program — ...